Royce & Associates’s ChemoCentryx, Inc. CCXI Stock Holding History

Royce & Associates’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-32,900	Closed	-$82K	–	1110
2016 Q1	$82K	Sell	32,900 -400	-1%	-$1.46K	﹤0.01%	1069
2015 Q4	$270K	Sell	33,300 -21,700	-39%	-$154K	﹤0.01%	1062
2015 Q3	$333K	Sell	55,000 -15,000	-21%	-$108K	﹤0.01%	1077
2015 Q2	$576K	Hold	70,000	–	–	﹤0.01%	1072
2015 Q1	$529K	Hold	70,000	–	–	﹤0.01%	1077
2014 Q4	$478K	Hold	70,000	–	–	﹤0.01%	1136
2014 Q3	$315K	Hold	70,000	–	–	﹤0.01%	1254
2014 Q2	$410K	Hold	70,000	–	–	﹤0.01%	1245
2014 Q1	$464K	Sell	70,000 -212,000	-75%	-$1.47M	﹤0.01%	1238
2013 Q4	$1.63M	Buy	+282,000	New	+$1.45M	﹤0.01%	1102

Other funds holding CCXI

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Royce & Associates's CCXI Position: Q2 2016 in Review

Royce & Associates sold out of ChemoCentryx, Inc. (CCXI) in Q2 2016, closing a stake of 32,900 shares — an estimated $82K sold.

Royce & Associates first reported a position in CCXI in Q4 2013 and held it in 10 quarters. The position peaked at $1.63M in Q4 2013. 77 funds tracked by Wall St. Rank hold CCXI as of Q2 2016.

Royce & Associates reported no remaining ChemoCentryx, Inc. position as of Q2 2016 after selling out during the quarter.
Royce & Associates sold 32,900 ChemoCentryx, Inc. shares in Q2 2016, an estimated $82K.
Royce & Associates first reported a position in ChemoCentryx, Inc. in Q4 2013 and held it in 10 quarters.
Royce & Associates's ChemoCentryx, Inc. position peaked at $1.63M in Q4 2013.
77 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2016.

Based on Royce & Associates's 13F filing for Q2 2016, filed 8 Aug 2016.